Abstract:Purpose: Adding targeted therapies to chemotherapy in metastatic colorectal cancer (CRC) improves response rates and survival. KRAS is a predictive indicator for anti-epidermal growth factor receptor (EGFR) treatments. The most important reasons for KRAS discordance are intratumoral heterogeneity and incorrect mutation analysis. Evaluating the status of KRAS in primary and metastatic lesions becomes even more crucial to ensure efficient usage of anti-EGFR treatments. Methods: Patients with metastatic CRC, whose primary disease and liver and/or lung metastases were operated, were retrospectively evaluated, and KRAS assessment was performed on 31 patients who were suitable for DNA analysis. Pyrosequencing with polymerase chain reaction (PCR) was used for KRAS analysis. Results: The median age of 31 patients diagnosed with rectal cancer (N=13) and colon cancer (N=18) was 63 years (range 33-73). Metastasectomy locations included the liver (N=27), lung (N=3), and both lung and liver (N=1). KRAS discordance was detected in 22% (7/31) of the patients. While 3 patients with detected discordance had mutated KRAS in the primary material, wild type KRAS was detected in their liver or lung lesions. On the other hand, while 4 patients had wild type KRAS in the primary material, mutated KRAS was determined in their liver or lung lesions. The McNemar test revealed no significant discordance between primary and metastatic disease (p=1.00). No progression free survival (PFS) difference was detected between patients with determined discordance and patients with undetermined discordance (10.6 vs 14.7 months, p=0.719). Conclusion: This is the first study to evaluate KRAS discordance between primary and metastasis in CRC patients, who underwent metastasectomy, together with survival data. In the literature and recent studies with large patient numbers in which modern KRAS tests were used, the KRAS discordance rate varies between 3-12%. In our study, a higher KRAS discordance (22%) was detected, and no survival difference was determined between patients with or without discordance. In recent years, the rising interest in borderline resectable disease may bring forward discussions related to which material the KRAS status should be analyzed.

Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review

KRAS mutation status between left- and right-sided colorectal cancer: are there any differences in computed tomography?

Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue

KRAS Status and Resistance to Epidermal Growth Factor Receptor Tyrosine‐kinase Inhibitor Treatment in Patients with Metastatic Colorectal Cancer: a Meta‐analysis

Kras Mutations And Resistance To Egfr-Tkis Treatment In Patients With Non-Small Cell Lung Cancer: A Meta-Analysis Of 22 Studies

Evaluation of K-ras status concordance between primary colorectal cancer and related metastatic sites

KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma

KRAS Mutation Testing in Metastatic Colorectal Cancer.

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients with Metastatic Colorectal Cancer.

EGFR Mutations, Gene Amplification, and Protein Expression and KRAS Mutations in Primary and Metastatic Tumors of Nonsmall Cell Lung Cancers and Their Clinical Implications: A Meta-Analysis

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer

Mutations of KRAS and BRAF in Chinese Patients with Colorectal Carcinoma : Analyses of 966 Cases

Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients

Comparison of genomic profiling of patient-matched primary colorectal and surgical resected distant metastatic (stage IV) colorectal carcinoma for drug actionability

The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

KRAS genotypes predict metachronous colorectal cancer distant metastases after radical resections

K-Ras Mutation Detection in Liquid Biopsy and Tumor Tissue As Prognostic Biomarker in Patients with Pancreatic Cancer: a Systematic Review with Meta-Analysis

Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma